Australian Pharmacy Law & Practice addresses the current issues surrounding pharmacy law and regulation in Australia. As the Federal Government moves to implement a national registration and accreditation scheme for pharmacists, the pharmacy workforce is set to become more mobile as a result. There has been no greater time than now for practising pharmacists and students to understand the implications of current legislation and legal provisions underpinning their area of practice. This text provides a comprehensive analysis and discussion of the legislation and practice standards which are relevant to the practice of pharmacy. As well as covering specific pieces of legislation relating to the regulation of pharmacy practice and drug control, Australian Pharmacy Law & Practice includes important sections on legal concepts and the Australian constitution; the evolution of pharmacy practice and ethics; privacy legislation; occupational health and safety; and professional conduct including matters regarding investigation, discipline, and legal proceedings. Australian Pharmacy Law & Practice is the first text of its kind to address pharmacy practice in all its facets in the unique context of the Australian legal framework. It will be a valuable resource to students and overseas trained pharmacists seeking registration in Australia, as well as to qualified practitioners who seek to better understand the laws and standards that govern the profession. - Unique to the Australian marketplace – presently there is no publication dealing specifically with pharmacy law and ethics in this country - Each chapter includes – learning objectives, review questions and activities, and further readings - The inclusion of quotation from case law – provides an opportunity for readers to learn from history.

A new edition of this excellent pharmacy law text, fully updated and unique to the Australian marketplace. Australian Pharmacy Law and Practice 2nd edition is the key law and ethics resource for pharmacists and students. Fully revised and updated, this new edition provides an introduction to contemporary pharmacy practice in Australia, looking at the various laws, policies and standards that govern the profession. Australian Pharmacy Law and Practice 2nd edition features excerpts of the relevant legislation, addressing all the pharmacy laws and regulations Australia's pharmacists need to know. This updated pharmacy law text also includes a wealth of new content, such as pharmacy-specific case scenarios. Plus, all chapters are clearly mapped to the National Competency Standards Framework for Pharmacists 2010, which cover aspects of medicine regulation and pharmacy practice. An essential resource in the ever-changing area of pharmacy practice, this new edition of Australian Pharmacy Law and Practice is ideal for both pharmacy students wanting to understand the legal and regulatory implications of pharmacy practice and practicing pharmacists seeking clarification of their position in relation to the state and national legislation and regulation under which they practice. - End-of-chapter questions and activities - Further reading lists in every chapter - State-specific and up-to-date legislation - Clear, easy-to-follow layout - Additional case study resources on Elsevier's Evolve portal - Case scenarios incorporated throughout chapters. - Listing of National Competency Standards Framework for Pharmacists 2010 covered in each chapter.

This tenth edition of Dale and Appelbe's Pharmacy and Medicines Law, previously Dale and Appelbe's Pharmacy Law and Ethics, is your definitive guide to law relating to pharmacy and medicine practice in Great Britain. It covers law and professional regulation that all pharmacy and medicine professionals need to know.

This textbook offers a unique and accessible approach to ethical decision-making for practicing pharmacists and student pharmacists. Unlike other texts, it gives clear guidance based on the fundamental principles of moral philosophy, explaining them in simple language and illustrating them with abundant clinical examples and case studies. The strength of this text is in its emphasis on normative ethics and critical thinking, and that there is truly a best answer in the vast majority of cases, no matter how complex. The authors place high trust in a pharmacist’s moral judgment. This teaches the reader how to think, based on ethical principles, not necessarily what to think. This means navigating between the two extremes of overly theoretical and excessively prescriptive. The cogent framework given in this text uses the language of competing duties, identifying the moral principles at stake that create duties for the pharmacist. This is the balancing act of normative ethics, and of deciding which duties should prevail in a given clinical situation. This work presents a clear-cut pathway for resolving ethical dilemmas encountered by pharmacists, based on foundational principles and critical thinking. Presents a clear-cut pathway for resolving the ethical dilemmas encountered by pharmacists, based on foundational principles and critical thinking. Jon E. Sprague, RPh, PhD, Director of Science and Research for the Ohio Attorney General

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.